Physician profile
Roy A Kellerman
NPI 1083780605
$14,594.70
in general payments reported to CMS, 2019-2025
45 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,701 · 2020: $1,174 · 2021: $2,879 · 2022: $2,519 · 2023: $2,201 · 2024: $1,705 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,315 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,314.92 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,829.93 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,754.02 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,558.52 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,010.27 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $710.85 | 2021-2025 | |
| Abbott Laboratories | $699.22 | 2020-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $600.06 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.94 | 2019-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $528.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $512.80 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $478.17 | 2019-2024 | |
| Abbvie INC. | $468.09 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $405.00 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $379.72 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $316.37 | 2019-2025 | Zoryve |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $285.54 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $283.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $263.62 | 2019-2023 | Verquvo, Belsomra |
| Hikma Pharmaceuticals USA | $180.22 | 2019-2022 | |
| Amarin Pharma, INC. | $177.77 | 2020-2021 | |
| Antares Pharma, INC. | $170.26 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $151.46 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $125.37 | 2019-2023 | Gattex |
| Ironwood Pharmaceuticals, INC | $118.04 | 2021-2022 | |
| Horizon Therapeutics Plc | $92.98 | 2019-2021 | |
| Corcept Therapeutics | $89.27 | 2023-2025 | Korlym |
| Eyevance Pharmaceuticals LLC | $79.76 | 2021 | |
| Esperion Therapeutics, INC. | $78.70 | 2020-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $75.71 | 2020-2021 | |
| Ascensia Diabetes Care US INC. | $69.97 | 2023 | |
| Eisai INC. | $63.38 | 2021 | |
| Ardelyx, INC. | $52.33 | 2025 | Ibsrela |
| Lifescan, INC. | $52.30 | 2022 | |
| Halozyme INC | $49.40 | 2023 | |
| Sumitomo Pharma America, INC. | $45.76 | 2025 | Gemtesa |
| Allergan, INC. | $43.41 | 2019-2020 | |
| Ceribell, INC. | $41.34 | 2025 | Pocket Eeg Device |
| Amgen INC. | $36.10 | 2019 | |
| Atricure, INC. | $25.82 | 2025 | Atriclip Laa Exclusion System |
| Indivior INC. | $25.68 | 2025 | Sublocade |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.07 | 2022 | |
| Dexcom, INC. | $21.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.53 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $17.89 | 2019 | |
| Avion Pharmaceuticals | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Kellerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.